D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Hypoxia-related markers in the plasma of patients with advanced non-small cell lung cancer (NSCLC) and survival from chemotherapy: Southwest Oncology Group (SWOG) S0003
I. V. Galvin,Primo N. Lara,Quynh-Thu Le,Kari Chansky,John Crowley,Stephen K. Williamson,David R. Gandara,Paul H. Gumerlock +7 more
TL;DR: This phase III trial of carboplatin and paclitaxel +/- tirapazamine in advanced NSCLC hypothesized that modulation of plasma levels of one or more markers may correlate with patient outcome, and plasma from 144 patients has been analyzed by ELISA.
Journal ArticleDOI
A phase II trial of bryostatin in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: A California cancer consortium (CCC) trial
Robert J. Morgan,James H. Doroshow,Paul Frankel,Lucille Leong,Warren Chow,Gini F. Fleming,Agustin A. Garcia,Heinz Joseph Lenz,David R. Gandara +8 more
TL;DR: A Phase II pharmacokinetic trial of infusional bryostatin, a protein kinase C inhibitor isolated from the marine invertebrate bryozoan, Bugula Neritina, in combination with cisplatin in patients with recurrent platinum-sensitive or resistant ovarian cancer (OC) (E).
Journal ArticleDOI
Phi-53: (NCI#7251): Phase I trial of belinostat (PXD101) in combination with 13-cis-retinoic acid (13c-RA) in advanced solid tumor malignancies—A California Cancer Consortium NCI/CTEP sponsored trial.
Thehang Luu,Paul Frankel,Dean Lim,Mihaela C. Cristea,Jan H. Beumer,Leonard Joseph Appleman,Heinz-Josef Lenz,David R. Gandara,Richard Piekarz,Edward M. Newman +9 more
TL;DR: A phase I study of belinostat and 13c-RA in advanced solid tumors finds pre-clinical evidence suggests HDAC inhibitors enhance retinoic acid signaling with a synergistic impact in a variety of solid tumors.
Journal ArticleDOI
Phase II evaluation of paclitaxel by 96-hour infusion in stage IIIb and IV bronchioloalveolar carcinoma (BAC)
Journal ArticleDOI